Beyond Air, Inc.

Beyond Air develops and commercializes nitric oxide (NO) generator and delivery systems through its proprietary Lungfit platform. The company's primary approved product, Lungfit PH, treats persistent pulmonary hypertension of the newborn. The company is advancing multiple pipeline candidates across therapeutic areas, including Lungfit PRO for viral lung infections in hospitalized patients and Lungfit GO for nontuberculous mycobacteria treatment in home settings.

The company operates through three segments: Beyond Air, which focuses on pulmonary applications of nitric oxide delivery; Beyond Cancer, developing ultra-high concentration nitric oxide for solid and cutaneous tumors currently in Phase 1 trials; and NeuroNos, which develops selective neuronal nitric oxide synthase inhibitors for neurological conditions and autism spectrum disorder through a collaboration with Hebrew University of Jerusalem's Yissum Research Development Company.

Beyond Air is a commercial-stage medical device and biopharmaceutical company with 61 full-time employees, headquartered in Garden City, New York. The company was incorporated in Delaware and is publicly listed on Nasdaq. Beyond Air was founded in 2011 and previously operated under the name AIT Therapeutics before rebranding in June 2019.